JP2005511582A - 抗ムスカリン・エアゾール - Google Patents

抗ムスカリン・エアゾール Download PDF

Info

Publication number
JP2005511582A
JP2005511582A JP2003541756A JP2003541756A JP2005511582A JP 2005511582 A JP2005511582 A JP 2005511582A JP 2003541756 A JP2003541756 A JP 2003541756A JP 2003541756 A JP2003541756 A JP 2003541756A JP 2005511582 A JP2005511582 A JP 2005511582A
Authority
JP
Japan
Prior art keywords
antimuscarinic agent
tolterodine
inhalation
insufflation
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003541756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511582A5 (enExample
Inventor
ケー． カマラタ，スー
パトリス コルバサ，カレン
パランドラ，ジョー
リチャーズ，イバン
ピー． ワーコル，マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of JP2005511582A publication Critical patent/JP2005511582A/ja
Publication of JP2005511582A5 publication Critical patent/JP2005511582A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003541756A 2001-11-05 2002-11-04 抗ムスカリン・エアゾール Withdrawn JP2005511582A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33729801P 2001-11-05 2001-11-05
PCT/US2002/035335 WO2003039464A2 (en) 2001-11-05 2002-11-04 Antimuscarinic aerosol

Publications (2)

Publication Number Publication Date
JP2005511582A true JP2005511582A (ja) 2005-04-28
JP2005511582A5 JP2005511582A5 (enExample) 2005-12-22

Family

ID=23319948

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003541756A Withdrawn JP2005511582A (ja) 2001-11-05 2002-11-04 抗ムスカリン・エアゾール

Country Status (10)

Country Link
US (1) US20030144352A1 (enExample)
EP (1) EP1441706A2 (enExample)
JP (1) JP2005511582A (enExample)
AU (1) AU2002342313A1 (enExample)
BR (1) BR0206300A (enExample)
CA (1) CA2464217A1 (enExample)
MX (1) MXPA04003806A (enExample)
NO (1) NO20033079D0 (enExample)
TW (1) TW200300079A (enExample)
WO (1) WO2003039464A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US6974820B2 (en) * 2002-11-06 2005-12-13 Bridge Pharma, Inc. Methods for treating urinary incontinence and other disorders using trospium
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
US20060287347A1 (en) * 2005-06-21 2006-12-21 Aberg A K G Methods for treating smooth muscle disorders using trospium
US7390816B2 (en) * 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
US20070004766A1 (en) * 2005-07-01 2007-01-04 Aberg A K G Methods for relaxation of smooth muscle contractions using Trospium
EP2152232A4 (en) * 2007-05-30 2010-06-09 Microdose Therapeutx Inc METHOD AND COMPOSITIONS FOR OXYBUTYNINE ADMINISTRATION
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
WO2009080061A1 (en) * 2007-12-20 2009-07-02 Pharmathen S.A. Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof
US9180263B2 (en) 2009-07-01 2015-11-10 Microdose Therapeutx, Inc. Laboratory animal pulmonary dosing device
JP6017961B2 (ja) 2010-01-05 2016-11-02 マイクロドース セラピューテクス，インコーポレイテッド 吸入デバイスおよび方法
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
WO2018071435A1 (en) 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6717123A (enExample) * 1966-12-29 1968-07-01
US3505337A (en) * 1967-12-22 1970-04-07 Boehringer Sohn Ingelheim N - hydrocarbyl-substituted noratropinium,haloalkylates and o-acyl derivatives thereof
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE8800207D0 (sv) * 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
IL91377A (en) * 1988-09-14 1996-09-12 Nippon Shinyaku Co Ltd Derivatives of botinylamine glycolate
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
AU728395B2 (en) * 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
AU724563B2 (en) * 1996-07-29 2000-09-28 Pharmacia & Upjohn Ab Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6545046B2 (en) * 2000-08-30 2003-04-08 Theramax Inc. Method for enhanced delivery of oxybutynin and compositions thereof
PE20020547A1 (es) * 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma
US20030027856A1 (en) * 2001-06-29 2003-02-06 Aberg A.K. Gunnar Tolterodine metabolites

Also Published As

Publication number Publication date
CA2464217A1 (en) 2003-05-15
TW200300079A (en) 2003-05-16
WO2003039464A2 (en) 2003-05-15
MXPA04003806A (es) 2005-04-08
AU2002342313A1 (en) 2003-05-19
WO2003039464A3 (en) 2004-02-26
BR0206300A (pt) 2008-04-08
EP1441706A2 (en) 2004-08-04
US20030144352A1 (en) 2003-07-31
NO20033079D0 (no) 2003-07-04

Similar Documents

Publication Publication Date Title
JP3981357B2 (ja) 第４級アンモニウム化合物および抗ムスカリン剤としてのそれらの使用
JP2005511582A (ja) 抗ムスカリン・エアゾール
US7005449B2 (en) Tolterodine salts
US20090192187A1 (en) Dry powder formulation comprising an anticholinergic drug
AU2020202402A1 (en) Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses
CN101883562A (zh) 包含西替利嗪以及非β-2-肾上腺素受体激动剂、β-2-肾上腺素受体激动剂或消炎药的组合物及其用于治疗呼吸疾病的用途
US6538035B2 (en) Use of tolterodine to treat asthma
US20060110449A1 (en) Pharmaceutical composition
US8748488B2 (en) Methods and compositions for administration of oxybutynin
US20120101076A1 (en) Carbonate derivatives for the treatment of cough
AU2003288169B8 (en) Synergistic combination comprising roflumilast and (R,R) -formoterol
JP2018127489A (ja) 禁煙のためのβ−アドレナリン作動性インバースアゴニストの使用
JP2006506392A (ja) ムスカリン受容体アンタゴニストとしての第四級アンモニウム化合物
WO2005007145A1 (en) Pharmaceutical product comprising a beta-2 adrenoceptor agonist and an antihistamine
JP2008106028A (ja) 慢性疼痛の治療におけるフリバンセリンの使用
WO2005041969A1 (en) Pharmaceutical product comprising a beta-2 adrenergic agonist and an h1-receptor antagonist

Legal Events

Date Code Title Description
A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060601